Clinical-stage biotechnology company Bambusa Therapeutics Inc announced on Tuesday that the first patient has been dosed in the Phase Ib clinical trial of BBT002, a novel platform-in-a-molecule bispecific antibody targeting IL-4R alpha and IL-5, in patients with chronic obstructive pulmonary disease (COPD).
The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD, as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps. The company anticipates initial data in the second half of 2026.
According to Bambusa, BBT002 is designed to simultaneously inhibit IL-4/IL-13 and IL-5 signalling, two central and complementary drivers of type 2 inflammation that together shape disease expression across multiple organ systems and stages of life. By targeting both pathways in a single, long-acting molecule, BBT002 has the potential to deliver broader and more durable suppression of underlying disease biology than existing single-target therapies, offering a unified therapeutic approach across respiratory and other type 2 inflammatory conditions.
Sichuan Kelun-Biotech announces Phase III OptiTROP-Lung04 study results at 2026 ESMO
Bio-Thera reports promising BAT8008 - BAT1308 combination lung cancer clinical data at ESMO 2026
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
IHI and Bristol Myers Squibb launch initiative to expand cancer clinical trial access
Oracle partners AstraZeneca for AI-enabled healthcare innovation
GSK reports 61% response rate for investigational lung cancer drug
Omeros receives negative EU opinion on narsoplimab after re-examination
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201